A man who used the testosterone gel product AndroGel has sued drug maker AbbVie Inc., alleging that the company failed to adequately warn that the testosterone gel can increase the risk of blood clot complications like pulmonary embolism, deep vein thrombosis, stroke, heart attack and death. His wife has joined him as a plaintiff in the AndroGel lawsuit.
The AndroGel lawsuit alleges that the testosterone treatment “causes the hematocrit level to increase, thereby thickening the blood. This effect, if not monitored and controlled properly, can lead to life threatening cardiac events, strokes and thrombolytic events,” and thatAbbVie “misrepresented that AndroGel is a safe and effective treatment.”
Lead plaintiff Roger Gibby alleges that “after taking multiple doses of AndroGel, on or about Sept. 21, 2013, [he] suffered multiple blood clots in his lungs and legs,” conditions known as pulmonary embolism and deep vein thrombosis. If these blood clots break loose and travel to the heart or brain, they can cause a heart attack, stroke or death.
Gibby says had he known the true risks associated with the use of testosterone medications, including AndroGel, “he would not have consumed AndroGel, and would not have incurred the injuries or damages he did as a result of his use of AndroGel,” the lawsuit continues.
The couple’s AndroGel lawsuit lawyer cites a study published in the Journal of the American Medical Association noting that many men who take advantage of testosterone replacement therapy have not actually been tested for low levels of the hormone, leading to doubts about the company’s claim in 2003 that “up to 20 million men” may be affected by the condition.
Moreover, the symptoms of “Low-T,” as commercials term the disorder, are “all general symptoms that are often a result of aging, weight gain, or lifestyle, rather than low testosterone.” The doctor who developed the quiz used on the company’s website reportedly called it a “crappy questionnaire.”
On the other hand, medical literature, including three studies cited regarding testosterone side effects, indicate that the risk of death, heart attack and stroke could increase by as much as 30%. In 2010, a study for the New England Journal of Medicine was discontinued after an exceedingly high number of men in the testosterone group suffered adverse events, the lawsuit states.
The lawsuit goes on to allege that AbbVie “purposefully downplayed, understated and outright ignored the health hazards and risks associated with using” the testosterone replacement therapy as a result of “Low-T.”
The AndroGel side effects lawsuit is Roger Gibby, et al. v. AbbVie Inc., et al., Case No. 14-cv-917, in the U.S. District Court for the Northern District of Illinois.
If you or someone you know used AndroGel or similar testosterone gel or cream products and suffered from a heart attack, stroke, pulmonary embolism, deep vein thrombosis or other blood clot complication, take action. Learn about legal remedies available to you at the Testosterone Gel (T-Gel) Lawsuit & Testosterone Cream Side Effects Class Action Lawsuit Investigation. You can fill out the case submission form for a free evaluation. An AndroGel lawsuit lawyer will contact you to review your potential case along with a no-cost legal consultation. These adverse events can have serious ramifications and any legal remedy could defray medical bills and other costs.
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
©2008 – 2014 Top Class Actions® LLC
Various Trademarks held by their respective owners
Please note: Top Class Actions is not a settlement administrator or law firm. Top Class Actions is a legal news source that reports on class action lawsuits, class action settlements, drug injury lawsuits and product liability lawsuits. Top Class Actions does not process claims and we cannot advise you on the status of any class action settlement claim. You must contact the settlement administrator or your attorney for any updates regarding your claim status, claim form or questions about when payments are expected to be mailed out.